Mandate

Vinge acts for SUSI Partners on its acquisition of the Lyngsåsa wind park

September 09, 2019 M&A Energy

Vinge has acted for SUSI Partners, manager of the SUSI Renewable Energy Fund II, in connection with its acquisition of the Lyngsåsa wind park in Alvesta municipality.

As part of the transaction, SUSI Partners has secured a long-term fixed price Power Purchase Agreement (PPA) and arranged for debt financing with Hamburg Commercial Bank for the project.

The Lyngsåsa wind park will consist of 22 Vestas V150 turbines with a total capacity of 94.6 MW. The project has been developed from greenfield by BayWa r.e., with operations scheduled to begin in 2021. BayWa will also manage the complete engineering, procurement and construction (EPC) of the turnkey project. Annual production will be around 315GWh, providing electricity to the equivalent of 80,000 households, while saving approximately 93,000 tons of CO2 emissions each year.

Vinge’s team was headed by M&A partner Peter Sundgren and included e.g. partners Christoffer Thalin (M&A), Johan Cederblad (permits), Thomas Sjöberg (permits), Assur Badur (real estate), Matthias Pannier (M&A), Robert Deli (real estate); counsel Sofia Törnroth Nyberg (project financing), Maria Schultzberg (tax), Fredrik Christiansson (project financing); and associates Jack Bengtsson (project financing), Axel Jansson (project financing), Hampus Olsson (real estate), Karolina Cohrs (real estate), Vilhelm Rondahl (M&A) and Rasmus Perdahl (M&A).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026